Recombinant Human AKR1B10 Protein ，GST

AKR1B10, a member of the aldo-keto reductase (AKR) superfamily, is a key enzyme involved in the metabolism of various endogenous and exogenous substrates, including steroids, drugs, and carbonyl compounds. Research on AKR1B10 has gained significant attention due to its potential implications in cancer progression, diabetes, and other metabolic disorders. Particularly, AKR1B10 has been found to be overexpressed in several types of cancer, where it may contribute to tumorigenesis by altering key metabolic pathways and facilitating the detoxification of reactive aldehydes. Furthermore, its enzymatic activity can affect the pharmacokinetics of certain drugs, leading to variations in therapeutic efficacy and toxicity. As a result, scientists are increasingly focused on characterizing the biochemical properties, substrate specificity, and regulatory mechanisms of AKR1B10. Understanding its function and regulation could provide insights into its role in disease pathology and could help identify potential therapeutic targets for intervention. Recent advances in recombinant protein technology have enabled the production and purification of AKR1B10 for detailed structural and functional studies, facilitating the exploration of its mechanisms of action and interactions with various ligands. Through these investigations, researchers aim to delineate the therapeutic potential of targeting AKR1B10 in relevant disease contexts, thereby contributing to the development of innovative strategies for treatment and management.